News

Imnovid® approved by NICE for relapsed and/or refractory myeloma patients

The National Institute for Health and Care Excellence (NICE) has approved the routine use of Imnovid (pomalidomide) in combination with dexamethasone for relapsed and/or refractory myeloma patients who have had at least three previous lines of treatment including both Velcade® and Revlimid® (lenalidomide). The announcement comes after previous negative guidance for patients who had two…

Details

NICE issues third draft “no” on Revlimid® at first relapse in myeloma

The National Institute for Health and Care Excellence (NICE) has published another draft “no” on Revlimid (lenalidomide) as a treatment for non-transplant eligible myeloma patients at first relapse who have previously received Velcade® (bortezomib). Ongoing since 2014, this is the third appraisal consultation on Revlimid to receive negative guidance in this setting and has been…

Details

Kyprolis® gets a draft ‘no’ from NICE

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance for Kyprolis (carfilzomib) recommending that it should not be made available on the National Health Service. The guidance forms part of the assessment for Kyprolis to be used in combination with Revlimid and/or dexamethasone in myeloma patients who have received at…

Details

2016 ASH abstracts now available to view

This year’s American Society for Hematology (ASH) Annual Meeting final programme and abstracts are now available to view. Over 500 clinical and non-clinical abstracts specifically related to myeloma are being presented at the meeting being held on 3 – 6 December 2016 in San Diego, USA. Highlights include: Latest results from the National Myeloma XI…

Details

Collaboration helps boost evaluation of immunotherapy in myeloma

The biopharmaceutical company, Adaptimmune Therapeutics, has announced that it has entered into a collaboration with Merck & Co to evaluate the use of its NY-ESO SPEAR® (specific peptide enhanced affinity receptor) T cell therapy in combination with Merck’s anti PD-1 inhibitor Keytruda® (pembrolizumab) in relapsed and/or refractory myeloma patients. Early phase trials are expected to…

Details

EMA to assess market authorisation application for Aplidin® in myeloma

PharmaMar, the Spanish pharmaceutical company, has announced that the European Medicines Agency (EMA) has agreed to assess its market authorisation application for Aplidin (plitidepsin) in combination with dexamethasone as a treatment for relapsed and/or refractory myeloma patients. Aplidin is a novel anticancer drug of marine origin extracted from the invertebrate Aplidium albicans which specifically targets…

Details

EMA provides open access to clinical trial data

The European Medicines Agency (EMA) has adopted a new policy to provide open access to clinical reports for new medicines for human use that are authorised in the European Union. The aim is to increase transparency concerning clinical trials with protocols and data, whether positive or negative, being made publicly available. It is hoped that…

Details